EcoDrugPlus

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSOTSG00005003314
Gene Symbol: HCK
1 Cross references
196 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSOTSG00005017797
Gene Symbol: ITK
1 Cross references
201 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSOTSG00005026822
Gene Symbol: IMPDH1B
1 Cross references
254 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSOTSG00005024879
Gene Symbol: IMPDH1B
1 Cross references
254 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1b

Ensembl ID : ENSOTSG00005027023
Gene Symbol: IMPDH1B
1 Cross references
254 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSOTSG00005045878
Gene Symbol: IMPDH2
1 Cross references
194 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSOTSG00005042882
Gene Symbol: JAK1
1 Cross references
159 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSOTSG00005037400
Gene Symbol: JAK1
1 Cross references
204 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSOTSG00005004676
Gene Symbol: JAK1
1 Cross references
158 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSOTSG00005008868
Gene Symbol: JAK1
1 Cross references
205 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSOTSG00005027989
Gene Symbol: JAK2A
1 Cross references
193 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSOTSG00005046619
Gene Symbol: JAK2A
1 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).